M
Mona Sadeghalvad
Researcher at Tehran University of Medical Sciences
Publications - 25
Citations - 253
Mona Sadeghalvad is an academic researcher from Tehran University of Medical Sciences. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 5, co-authored 16 publications receiving 142 citations. Previous affiliations of Mona Sadeghalvad include Kermanshah University of Medical Sciences & Education and Research Network.
Papers
More filters
Journal ArticleDOI
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
Amir Hossein Mansourabadi,Mona Sadeghalvad,Hamid-Reza Mohammadi-Motlagh,Nima Rezaei,Nima Rezaei +4 more
TL;DR: It seems that treatment with immunotherapy along with other standard cares could be an effective and safe approach to modulate the immune system and improvement of clinical outcomes.
Journal ArticleDOI
Influenza vaccine: Where are we and where do we go?
Mohsen Keshavarz,Hamed Mirzaei,Maryam Salemi,Fatemeh Momeni,Mohammad Javad Mousavi,Mohammad Javad Mousavi,Mona Sadeghalvad,Yaser Arjeini,Farid Solaymani-Mohammadi,Javid Sadri Nahand,Haideh Namdari,Talat Mokhtari-Azad,Farhad Rezaei +12 more
TL;DR: The lack of viral genome in VLP and M2e‐based vaccines addresses safety concern associated with existing attenuated vaccines and could contribute to better treatment of influenza.
Journal ArticleDOI
Immune microenvironment in different molecular subtypes of ductal breast carcinoma
TL;DR: It is important to realize that different frequencies of immune cells in BC environment likely determine the patients’ prognosis and their survival in each subtype, therefore, elucidation of the distinct immune players in TME would be helpful toward developing targeted therapies in eachSubtype.
Journal ArticleDOI
Soybean Bowman-Birk Protease Inhibitor (BBI): Identification of the Mechanisms of BBI Suppressive Effect on Growth of Two Adenocarcinoma Cell Lines: AGS and HT29
TL;DR: Investigation of the effects of BBI on proliferation of and VEGF secretion by two cell lines suggests BBI as a potent inhibitor of gastric cancer progression and inhibition of M MP-2, MMP-9 and V EGF secretion is one of the mechanisms of anti-angiogenic effect of B BI.
Journal ArticleDOI
In vivo anti-inflammatory efficacy of the combined Bowman-Birk trypsin inhibitor and genistein isoflavone, two biological compounds from soybean.
TL;DR: The results showed that treatment with the combination of BBI and genistein greatly led to more reduced serum levels of tumor necrosis factor (TNF)‐α and interferon (IFN)‐γ compared with the treatments of B BI alone, the BBI‐genistein conjugate, and genismoin alone, respectively.